Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Quality, availability and suitability of antimicrobial stewardship guidance: a multinational qualitative study.
Linde-Ozola Z, Classen AY, Giske CG, Göpel S, Eliakim-Raz N, Semret M, Simonsen GS, Vehreschild JJ, Jørgensen SB, Kessel J, Kleppe LKS, Oma DH, Vehreschild MJGT, Vilde A, Dumpis U; PILGRIM study group. Linde-Ozola Z, et al. JAC Antimicrob Resist. 2024 Mar 14;6(2):dlae039. doi: 10.1093/jacamr/dlae039. eCollection 2024 Apr. JAC Antimicrob Resist. 2024. PMID: 38486662 Free PMC article.
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Fein L, Lazaretti N, Chuken YL, Benfield JRGR, Mano MS, Lobaton J, Korbenfeld E, Damian F, Lu DR, Mori A, Patyna SJ, Franco S. Fein L, et al. Clin Drug Investig. 2023 Sep;43(9):707-708. doi: 10.1007/s40261-023-01305-3. Clin Drug Investig. 2023. PMID: 37695417 Free PMC article. No abstract available.
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Fein L, Lazaretti N, Chuken YL, Benfield JRGR, Mano MS, Lobaton J, Korbenfeld E, Damian F, Lu DR, Mori A, Patyna SJ, Franco S. Fein L, et al. Clin Drug Investig. 2023 Sep;43(9):699-706. doi: 10.1007/s40261-023-01294-3. Epub 2023 Aug 18. Clin Drug Investig. 2023. PMID: 37594640 Free PMC article.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
103 results